CSIMarket
 
Galectin Therapeutics Inc   (GALT)
Other Ticker:  
 
 
Price: $1.8600 $-0.02 -1.064%
Day's High: $1.92 Week Perf: 0.00
Day's Low: $ 1.81 30 Day Perf: 7.51 %
Volume (M): 27 52 Wk High: $ 2.47
Volume (M$): $ 51 52 Wk Avg: $1.79
Open: $1.92 52 Wk Low: $1.28



 Market Capitalization (Millions $) 111
 Shares Outstanding (Millions) 60
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -45
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Galectin Therapeutics Inc
Galectin Therapeutics Inc is a publicly traded, clinical-stage biotechnology company that is focused on developing therapies to treat fibrosis and cancer. In particular, the company is working on developing galectin inhibitors, which are drugs designed to block the activity of galectins, which are proteins involved in inflammation, cell growth, and cell death.

The company was founded in 2000 and is based in Norcross, Georgia. Its lead product candidate is GR-MD-02, a galectin-3 inhibitor that is being developed to treat a variety of fibrotic diseases, including non-alcoholic steatohepatitis (NASH), or fatty liver disease, and liver fibrosis caused by hepatitis C virus (HCV) infection. The company is also exploring the use of galectin inhibitors to treat various types of cancer.

Galectin has completed multiple clinical trials of GR-MD-02 for NASH and liver fibrosis, including a phase 2b clinical trial of GR-MD-02 in patients with NASH cirrhosis. The company is currently conducting a phase 2 clinical trial of GR-MD-02 in combination with KEYTRUDA for the treatment of metastatic melanoma.

In addition to GR-MD-02, Galectin has a pipeline of galectin inhibitors in various stages of development, including GR-e, a galectin-1 inhibitor being developed for the treatment of cancer, and GM-CT-01, a galectin-9 inhibitor being developed for the treatment of asthma and other inflammatory diseases.

Overall, Galectin Therapeutics is focused on developing innovative therapies for serious diseases with unmet medical needs, particularly fibrotic diseases and cancer.


   Company Address: 4960 Peachtree Industrial Blvd. Norcross 30071 GA
   Company Phone Number: 620 -3186   Stock Exchange / Ticker: NASDAQ GALT
   GALT is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Galectin Therapeutics Inc

Galectin Therapeutics Inc Discloses Operating Loss of $9.166 Million in Q3 20232.

Galectin Therapeutics Inc (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, recently announced its financial results and provided a business update for the three months ended on September 30, 2023. According to the Company's Quarterly Report on Form 10-Q, it reported an operating loss of $-9.166 million for that period. Although the revenue has not yet been declared, it is important to analyze the business's performance to gain a better understanding of its current conduct.
During the same quarter in 2022, Galectin Therapeutics Inc recorded an operating loss of $-8.122 million. This suggests that the company has encountered certain challenges in pursuing a successful business strategy, as entities often face uncommonly difficult periods. The deficit has expanded to $-14.035 million in the third quarter of 2023, which further accentuates the hurdles that Galectin Therapeutics Inc is currently facing.

Galectin Therapeutics Inc

The Major Pharmaceutical Preparations Company Causes Investment Stir as Galectin Therapeutics Inc Faces Revenue Setbacks in Q2 2023


Introduction
Galectin Therapeutics Inc is a rapidly growing biotechnology company that specializes in the development and commercialization of novel therapies to treat fibrotic diseases and cancer. In recent years, the company has garnered attention due to its promising pipeline of potential treatments. However, the recent financial statements have shown some moderations in revenue that have caught the shareholders off guard. This article aims to delve into the recent revenue dynamics at Galectin Therapeutics Inc and shed light on how the company is strategizing to overcome these challenges.
Moderations in Revenue: A Change in Expectations
During the fiscal period of April to June 2023, shareholders noticed some unforeseen moderations in Galectin Therapeutics Inc's revenue. The company reported an operating loss of $-9.003 million during this time, representing a growth relative to the previous year's second quarter operating loss of $-9.662 million. This deviation from expectations has raised concerns among shareholders, prompting them to analyze the situation more closely.

Galectin Therapeutics Inc

Galectin Therapeutics Inc Reports $40 Million Net Loss in Q1 2023; Faces Decline in Industry Ranking and Operating Performance

Galectin Therapeutics Inc, a biotechnology company that specializes in developing novel therapies for fibrosis and cancer, recently announced a net loss of $-40 million during 12 month ending in the first quarter 2023. The company is yet to announce revenue for the period, but industry experts have been keeping a close watch on the firm's financial figures.
The Major Pharmaceutical Preparations industry has seen a rise in income per employee across 173 other companies, but Galectin Therapeutics Inc's ranking has dropped from 0 to 2551 in comparison to the forth quarter 2022. Despite this decline, experts anticipate an improvement in the company's financial performance in the future.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com